Moss, 7 November 2019
Gentian Diagnostics AS announces its results for the third quarter of 2019. The highlights include:
• Record sales revenues of MNOK 13.1 in 3Q19, up from MNOK 10.4 in 3Q18, totaling a 26 % growth YOY
• Record sales revenue for the first nine months of MNOK 33.9 representing 18% growth compared to
the same period of 2018
• In July, Gentian and Beckman Coulter, one of the top 5 global diagnostics companies, prolongated
their partnership agreement for Cystatin C by 6 years
• In August, Gentian announced the sales channel agreement for fCAL® turbo between Roche
Diagnostics and Gentian’s sales partner Bühlmann Laboratories AG
Please find the report and results presentation enclosed. The documents will also be made available on www.gentian.no.
For further information, please contact:
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525